Cyclosporine a-nanosuspension: formulation, characterization and in vivo comparison with a marketed formulation

Sci Pharm. 2010 Apr-Jun;78(2):345-61. doi: 10.3797/scipharm.0908-12. Epub 2010 Apr 26.

Abstract

Cyclosporine A-nanosuspensions were prepared using zirconium oxide beads as a milling media, Poloxamer 407 as a stabilizer and distilled water as an aqueous medium using the Pearl Milling technique. The optimized formulation was characterized in terms of particle size distribution, surface morphology, drug-surfactant interaction, drug content, saturation solubility, osmolarity, and stability. The nanoparticles consisting of Poloxamer-bound cyclosporin A with a mean diameter of 213 nm revealed a spherical shape and 5.69 fold increased saturation solubility as compared to the parent drug. The formulation was found to be iso-osmolar with blood and stable up to 3 months at 2â8ÂC. In-vivo studies were carried out in albino rats and the pharmacokinetic parameters were compared with a marketed formulation, which indicated better results of the prepared formulation than the marketed one.

Keywords: Cyclosporine A; Nanosuspension; Osmolarity; Poloxamer; Scanning electron microscopy.